This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech ETFs Poised to Benefit From Coronavirus
by Neena Mishra
Rising investor interest in coronavirus related stocks will benefit these ETFs
Top ETF Stories of April Likely to Hit Headlines Again in May
by Sanghamitra Saha
Energy, gold, online retail and biotech were the most-discussed ETF areas in April and could continue to be so in May.
Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir
by Sweta Jaiswal, FRM
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Coronavirus Scare Supports These Biotech ETFs & Stocks
by Sanghamitra Saha
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
ETF Strategies to Play the Rising Virus-Induced Volatility
by Sanghamitra Saha
Try these ETF strategies to counter the renewed risk of the spread of coronavirus.
Emergency Fed Cut Less Effective: ETFs That Should Survive
by Sanghamitra Saha
Why the Fed's emergency rate cut failed to energize markets and why these ETFs should stay steady (gain or lose little) amid the current scenario.
Stimulus Hopes Triumph Over Virus: 5 Top ETF Picks for March
by Sanghamitra Saha
These top-ranked ETFs could prove profitable for investors in the month of March.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
ETFs to Play as Goldman Lowers US Q1 GDP Outlook
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can tap as aggravating coronavirus outbreak lead to a cut in U.S. GDP growth forecast.
Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas
by Sanghamitra Saha
Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE